<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="573">
  <stage>Registered</stage>
  <submitdate>12/09/2005</submitdate>
  <approvaldate>16/09/2005</approvaldate>
  <actrnumber>ACTRN12605000420640</actrnumber>
  <trial_identification>
    <studytitle>Randomised 12 month trial of Non-Invasive Ventilation (NIV) with or without oxygen versus oxygen alone in treatment of sleep disordered breathing in Cystic Fibrosis</studytitle>
    <scientifictitle>Randomised 12 month trial of Non-Invasive Ventilation (NIV) with or without oxygen versus oxygen alone in treatment of sleep disordered breathing in Cystic Fibrosis</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil known</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Cystic Fibrosis</healthcondition>
    <conditioncode>
      <conditioncode1>Human genetics and inherited disorders</conditioncode1>
      <conditioncode2>Cystic fibrosis</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Patients will be randomised to oxygen alone or NIV with or without oxygen, as titrated during polysomnography to maintain oxygen saturation &gt;=90% in all sleep stages. Patients will be followed-up over 12 months. Repeat sleep studies at 3, 6 and 12 months. They will be censored if they undergo lung transplant or die. They cease the trial if defined as a 'treatment failure'</interventions>
    <comparator>Control group was oxygen alone</comparator>
    <control>Active</control>
    <interventioncode>Treatment: Devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Number of treatment failures (PaCO2&gt;60 or an increase &gt;10mmHg from baseline; or increase TcCO2&gt;10 from awake to sleep).</outcome>
      <timepoint>This is time-to-event data, so "treatment failure" will be recorded if it occurs any time from baseline (day 0) within the 12 month time frame of the study.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Change in daytime PaCO2 from baseline to 12 months.</outcome>
      <timepoint>12 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Quality of life</outcome>
      <timepoint>Baseline, 3 months, 6 months, 12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Sleep quality</outcome>
      <timepoint>Baseline, 3 months, 6 months, 12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Lung function</outcome>
      <timepoint>Baseline, 3 months, 6 months, 12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Days on IV antibiotics</outcome>
      <timepoint>Total days on IV antibiotics within the 12 month study</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Days in hospital (excluding trial measurement days)</outcome>
      <timepoint>Total days in hospital (excluding trial measurement days) within the 12 month study</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Direct medical costs</outcome>
      <timepoint>Total direct medical costs within the 12 month study</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Stable CF adults with total sleep time minimum average oxygen saturation &lt;=90%</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Acute unstable hypercapnic respiratory failure (PaCO2&gt;60; eligible for randomisation after acute treatment if stable off NIV for a minimum of two weeks); severe co-existing disease; persistent pneumothoraces; sputum colonised with burkolderia cepacia.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Sealed opaque envelopes</concealment>
    <sequence>Computer-generated randomisation table. Block randomisation</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>1/06/1998</anticipatedstartdate>
    <actualstartdate>11/06/1998</actualstartdate>
    <anticipatedenddate />
    <actualenddate>16/04/2010</actualenddate>
    <samplesize>40</samplesize>
    <actualsamplesize>31</actualsamplesize>
    <recruitmentstatus>Closed: follow-up complete</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Government body</primarysponsortype>
    <primarysponsorname>SWSAHS</primarysponsorname>
    <primarysponsoraddress>Level 11, KGV Building
Missenden Road
Camperdown NSW 2050
</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>NHMRC Progress Grant</fundingname>
      <fundingaddress>Director, Research Administration Section
National Health and Medical Research Council
GPO Box 1421
Canberra ACT 2601</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>None</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Last participant recruited 16/4/2010. Recruitment halted 2015 as no participant recruited in last 5 years. Data analysis ongoing.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Royal Prince Alfred Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>29/05/1998</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Prince Charles Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>21/11/2002</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Peter Bye</name>
      <address>Department of Respiratory Medicine
Royal Prince Alfred Hospital
11 West
Missenden Road
Camperdown NSW 2050</address>
      <phone>+61 2 95157427</phone>
      <fax>+61 2 95158196</fax>
      <email>peter.bye@sydney.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Tiffany Dwyer</name>
      <address>Department of Respiratory Medicine
Royal Prince Alfred Hospital
11 West
Missenden Road
Camperdown NSW 2050</address>
      <phone>+61 2 95155234</phone>
      <fax>+61 2 95158196</fax>
      <email>tiffany.dwyer@sydney.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Peter Bye</name>
      <address>Respiratory Medicine
Level 11
RPA Hospital
Missenden Road
Camperdown NSW 2050</address>
      <phone>+61 2 9515 7427</phone>
      <fax />
      <email>peter.bye@sydney.edu.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>